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1. Introduction 
Few drugs have made such a profound impact on modern medicine as antibiotics. With the 
discovery of sulfonamides, β-lactams, and subsequent antibiotic classes after World War II, 
bacterial infections with often fatal outcomes literally became curable overnight. These 
“magic bullets,” however, suffer from a serious drawback; the use (and misuse) of 
antibiotics induces selection pressure resulting in the development of resistance traits in 
bacterial populations. The process is augmented by short generation times of bacteria 
enabling rapid mutation and selection of resistant strains, and a horizontal transfer of 
resistance genes. Bacterial pathogens resistant to more than one, or even most clinically used 
antibiotics, have become common (Fischbach & Walsh, 2009). Faced with the fact that a 
renewed pre-antibiotic era might be just around the corner, the World Health Day 2011 
campaign “Antimicrobial resistance and its global spread” launched by the WHO offers a 
strategy to safeguard existing antibiotics for future generations, and contain the spread of 
antimicrobial resistance (World Health Organization, 2011). However, taking a more 
sensible approach in prescribing and using available antibiotic drugs will only help to put 
off the inevitable. In the battle against the ever-increasing multidrug resistance of 
pathogenic bacteria, we urgently need new alternatives to the currently available broad-
spectrum antibiotics. Here we review some current trends in antibiotic discovery focusing 
on the screening of natural products. 
This chapter is composed of four parts. We start by briefly reviewing the history of 
antibiotic discovery, gradually moving from its most fruitful era in the 1940’s and 50’s to the 
unexpected outcome decline in the genomic era. Next, we address two fundamental 
questions of antibiotic research in the post-genomic age; namely, where to look for novel 
antibiotics and how. Finally, we conclude with a concise discussion on the modification of 
natural scaffolds to be translated into functional drugs. 
2. History of antibiotic discovery 
2.1 The golden age of antibiotic discovery 
Before the discovery of prontosil, the forerunner of sulfonamide chemotherapeutics, the 
only available measures in combating bacterial infections, apart from practicing proper 
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hygiene, were vaccination and passive immunization. Although these approaches are still 
invaluable today, the advent of broad-acting antibacterial agents enabled rapid treatment of 
patients with infections even when the exact causative bacterial pathogen was unknown. 
Prontosil, later found to be a prodrug releasing folate antimetabolite sulfanilamide upon 
reduction in vivo, was a result of a screening campaign at Bayer, Germany in the early 
1930’s, aimed at finding synthetic dyes for the potential effect on hemolytic streptococcal 
infection (Greenwood, 2003). Although the premise that dyes in general should exert 
antibacterial activity turned out to be incorrect, prontosil paved the way for antimicrobial 
drugs, becoming the first commercially available antibacterial agent and remained in clinical 
use for 30 years. Moreover, it inspired new generations of sulfonamide chemotherapeutics, 
some of which remain on the market today. All major antibiotic classes that form pillars of 
antibacterial therapy were derived from natural sources − mostly microbial secondary 
metabolites (Molinari, 2009) − with the exception of sulfonamides and quinolones, inhibitors 
of bacterial DNA gyrase that were discovered in the 1960’s. 
The groundbreaking work of Rene Dubois, who studied antibiosis in pairs of soil 
microorganisms, eventually leading to the discovery of a mixture of peptidic antibiotics 
collectively termed tyrothricin (its component gramicidin is still in limited use), inspired 
Selman Waksman and Boyd Woodruff to adopt the principle in systematic search for novel 
antibiotics (Kresge et al., 2004). It is now well recognized that many microbes produce 
structurally extremely diverse, small molecules that are involved in complex intra- and 
interspecies signaling (Shank & Kolter, 2009). Antibiosis is only one of the many possible 
outcomes of such interaction, but is most readily detected: Waksman and Woodruff looked 
for growth inhibition zones surrounding single colonies of soil microorganisms cultured 
under different conditions and then isolated the active substance from pure cultures by 
activity-guided fractionation (Waksman & Woodruff, 1940). The same route led to the 
earlier serendipitous discovery of penicillin by Alexander Fleming in 1929 (Fleming, 1929). 
It took almost 15 years to scale up penicillin production and demonstrate its efficacy and 
safety. By that time numerous other antibiotic types were emerging (Fig. 1). The major 
source of antimicrobials turned out to be soil actinomycetes, such as the Streptomyces 
species, and various fungi. Considering the abundance of soil microbes (there are estimates 
of 109-1010 bacteria in a single gram of soil belonging to some 104 operational taxonomic 
units (Curtis et al., 2006; Gans et al., 2005)) the explosion in antibiotic discovery that began 
in the early 1940’s is not surprising from current perspective. However, not all species are 
equally represented. Moreover, many related bacteria or fungi produce the same or similar 
secondary metabolites. For example, streptothricin was found in ~10%, streptomycin in 
~1%, and tetracycline and actinomycin in ~0.1% of randomly collected soil actinomycetes 
(Baltz, 2007). So when the most abundant antibiotics were identified the pace of natural 
antibiotic discovery gradually slowed down (Baltz, 2007, 2008), finally culminating in a 30-
year-gap in launching an antibiotic with a novel scaffold to the market (Fig. 1). The situation 
was exacerbated by ever stricter regulatory demands on safety and efficacy of drugs, the 
wrongful perception that bacterial infections no longer posed a severe threat to human 
health, as well as the unfavorable economics of antibacterial development (revenue from 
antibiotics is significantly lower compared to drugs indicated for chronic diseases), leading 
to a withdrawal of Big Pharma from the antibiotic business (Brötz-Oesterhelt & Sass, 2010; 
Fischbach & Walsh, 2009; Projan, 2003). Meanwhile, the development and spread of 
bacterial resistance was steadily incising into our antibacterial arsenal (Fig. 1). 
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Fig. 1. Timeline for the introduction of major, broad-spectrum antibiotic classes for systemic 
application in the clinic, and documented occurrence of bacterial resistance (adapted from 
(Brötz-Oesterhelt & Sass, 2010)). The asterisk denotes two new antibiotic classes with single 
representatives (i.e., lipopeptide daptomycin, and pleuromutulin retapamulin), both of 
which are intended for topical application. However, analogues for systemic application 
(oral or i.v.) are being developed (also see section 3.1.4). ESBL – extended spectrum  
β-lactamase, VISA – vancomycin intermediately resistant Staphylococcus aureus,  
VRE – vancomycin-resistant Enterococcus, VRSA – vancomycin highly resistant S. aureus. 
2.2 The disappointing investment in combinatorial chemistry and high-throughput 
screening in antibiotic discovery 
Rediscovery of known antibiotics from screening microbial extracts and the development of 
highly effective synthetic (fluoro)quinolones caused a shift in antimicrobial drug R&D strategy 
in the industry. The search for antibiotics occurring in the environment was mostly abandoned 
(although semisynthetic modification of natural scaffolds resulted in numerous improved 
antibiotics (Fischbach & Walsh, 2009)) and the screening efforts were once again invested in 
synthetic compounds. Since the early 1990’s combinatorial chemistry was employed to 
produce large libraries of compounds that demanded high-throughput assaying for activity. 
The advent of genomics and bioinformatics raised the hopes for identification of entirely new 
antibacterial targets by mining bacterial genomes. Genes conserved among bacteria but 
sharing no homology to eukaryotic counterparts were considered as potential targets, and 
their activity or expression were manipulated by mutation studies or knockout technology to 
examine whether their products were indispensable for bacterial survival in vitro. Following a 
functional analysis, selected targets were expressed using recombinant technology and 
purified. This allowed for setting up miniaturized inhibitory activity assays for screening vast 
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chemical libraries against isolated targets, as well as elucidation of targets’ structures to guide 
the subsequent optimization of leads. Despite enormous efforts in the last 20 years, however, 
the target-oriented drug discovery approach has not resulted in a single new antimicrobial 
chemotherapeutic. The reasons for that are multitude (reviewed in detail in (Baltz, 2006; Brötz-
Oesterhelt & Sass, 2010; Projan, 2003)). 
Firstly, the abandonment of whole-cell assays meant that cell penetrating capabilities were not 
a selection criterion for hits early in the discovery process. Therefore, most compounds that 
were highly active against an isolated target possessed no antimicrobial activity. Secondly, it 
appears that the properties of antibiotics in general do not conform to Lipinski’s rule (Lipinski 
et al., 2001); they are more polar and have a higher molecular weight than drugs for other 
indications (O'Shea & Moser, 2008). Chemical libraries, on the other hand, had mostly been 
designed to meet Lipinski’s criteria, and were thus likely biased against antibiotic compounds 
(Payne et al., 2007). Thirdly, inhibiting targets that were validated to be indispensible for 
bacterial survival in vitro does not necessarily lead to antibacterial effect in vivo. A prominent 
example is that of the type II fatty acid synthesis (FASII) pathway, intrinsic to bacteria: 
bacterial pathogens susceptible to FASII inhibitors in vitro were shown to be resistant to them 
when cultured in the presence of unsaturated fatty acids, or in vivo upon infection of rodents 
(Brinster et al., 2009). This indicates that bacteria can thrive in the nutrient-rich environment of 
the host by acquiring exogenous fatty acids, fully bypassing FASII pathway inhibition. 
Similarly, there is no guaranty that a target essential for viability of one bacterial strain will 
also be indispensible in others − as alternative biochemical pathways may be present that 
allow the targeted pathway to be circumvented (Gentry et al., 2003). 
2.3 Reappraising the natural products 
Historically, most drugs were derived from natural products. This trend continues today 
with ~50% of new small molecule drugs approved between the years 1981 and 2006 being 
either (semi)synthetic derivatives of compounds isolated from natural sources or synthetic 
mimetics of pharmacophores found in natural products (Newman & Cragg, 2007). In the 
field of antibacterial drugs, the trend is even more pronounced. Of 98 new molecular entities 
that were approved for human therapy in the same time period, only 23 are of totally 
synthetic origin, most of them (20) belonging to the quinolone group (Newman & Cragg, 
2007). A notable exception is linezolid, the first and, to date, the only representative of 
oxazolidinone chemotherapeutics developed from initial hits of cell-based screening efforts 
for antibacterial activity from a chemical library (Barbachyn & Ford, 2003; Slee et al., 1987). 
Among the 40 antibacterial compounds currently undergoing clinical trials, 20 are natural 
product-derived, 18 are synthetic, and 2 are of unknown origin (Butler & Cooper, 2011). 
Interestingly, while the ratio of natural product-derived vs. synthetic entities is roughly 1:1 
in phases I and II, the former predominate in phase III (i.e., 4:1). Moreover, there are more 
novel antibacterial classes among natural-product derived antibiotics compared to synthetic 
ones (a total of 7 new chemical scaffolds vs. 4) in the pipeline.  
Disappointment from antibacterial drug discovery in the genomic era brought a renewed 
interest in screening natural products (Baltz, 2008; Davies, 2011; Li & Vederas, 2009; Molinari, 
2009). Chemists have been isolating and analyzing secondary metabolites from plants, fungi, 
and bacteria for over 200 years, yet only a small percentage of species has been addressed (Li 
& Vederas, 2009). Undoubtedly, the natural supply of small molecules (sometimes referred to 
as parvome (Davies, 2011), from the Latin parvus meaning small) remains vast; however, there 
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is a problem accessing it. A majority (maybe up to 99%) of microbes, renowned for their rich 
and diverse metabolism, cannot be cultured in a laboratory, at least not under standard 
conditions (Amann et al., 1995; Li & Vederas, 2009). There are species of microbes that thrive in 
geographical or ecological niches, such as deep sea and thermal springs, or as symbionts of 
plants and animals, respectively, that still await to be explored. Besides rediscovery, a major 
obstacle that can impede natural product research is that some compounds are found in the 
environment in rather low concentrations, complicating their detection and isolation in 
quantities allowing structural and functional studies.  
Nevertheless, the thesis that the laborious screening for natural products with antibiotic 
activity is still worth the effort is supported by several facts. The parvome displays 
structural diversity unmatched by synthetic compounds; secondary metabolites often 
possess numerous chiral centers and display astonishing steric complexity. Furthermore, 
many natural antibiotics display complex and multilayer mechanisms of action that might 
not have been devised by rational design. Last but not least, millions of years of evolution 
have optimized antibiotics with respect to affinity and specificity for their targets, as well as 
physicochemical properties to penetrate bacterial envelopes (Butler & Buss, 2006; Pelaez, 
2006; Swinney & Anthony, 2011). Encouragingly, owing to the revival of screening for 
natural antimicrobials or reinspection of collections of old antibiotics in the last decade, we 
have witnessed attempts to develop antibiotics based on novel chemicals templates, such as 
lipopeptides, pleuromutilins, ramoplanins, and actinonins (Butler & Buss, 2006; Butler & 
Cooper, 2011). Drugs based on new scaffolds exerting novel mechanisms of action should be 
superior to existing antibiotic classes in the fight against multi-drug resistant pathogens 
(Butler & Buss, 2006). Of note, two such antibiotics have recently been approved for use in 
humans. Daptomycin, the first member of lipopeptide antibiotics, acts through a complex 
mechanism involving the disruption of the bacterial membrane leading to inhibition of 
DNA, RNA, and protein synthesis, and is indicated for the treatment of skin and skin 
structure infections caused by Gram-positive pathogens (Baltz et al., 2005). Retapamulin, a 
pleuromutilin type antibiotic with indications similar to those of daptomycin, selectively 
inhibits the P site of peptidyl transferase centre on the bacterial 50S ribosomal subunit, 
exhibiting a mechanism that differs from other protein synthesis-inhibiting antibiotics 
(Dubois & Cohen, 2010; Schlunzen et al., 2004). 
It is important to realize that all small molecular weight microbial products are active even 
though they might not induce antibiosis at concentrations found in the environment, 
suggesting their role as signaling molecules (Dufour & Rao, 2011; Miao & Davies, 2010; 
Shank & Kolter, 2009; Wyatt et al., 2010). Remarkably, this holds true even for well 
established antibiotics; a number of recent studies reported specific modulation of gene 
expression in different bacteria when exposed to subinhibitory concentrations of various 
antibiotics (Davies et al., 2006; Fajardo & Martinez, 2008; Linares et al., 2006). Reevaluation 
of known natural products for traits other than antibiosis might thus present another route 
leading to antibacterial drug discovery; inhibiting the production of metabolites that 
provide the producing microbe with an advantage in colonizing a certain niche could prove 
to be a fruitful approach in designing antimicrobials (Wyatt et al., 2010). 
3. Where do we search for natural antibiotics? 
The search for new antibiotics compounds goes hand in hand with the discovery of new 
(micro)organisms producing them. For this purpose the search has continued on land and at 
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sea with great expectations. Soil microorganism exploitation has not subsided and 
continuous effort is put into the expanding the diversity of actinomycetes and fungi, taking 
advantage of little explored ecological niches and developing new ways of growing 
previously uncultivable strains (Harvey, 2000). 
Almost all kinds of living things have the ability to produce secondary metabolites with 
antibiotic properties (Berdy, 2005), although this ability is not equally distributed among 
different species. Overall, it is clear that unicellular bacteria, eukaryotic fungi, and first of all 
filamentous actinomyces are the most frequent and most versatile producers. The 
filamentous actinomycetales species produce over 10,000 bioactive compounds, of which 
7600 derived from Streptomyces represent the largest group (45%) of bioactive microbial 
metabolites. Streptomycetes are demonstrably a rich source of compounds, but no more so 
than other members of the actinobacteria. In 2001 Watve et al. set about to produce a 
mathematical model that would estimate the number of undiscovered antimicrobials from 
the genus Streptomyces (Watve et al., 2001). They found that there are still around 150,000 
antimicrobials to be discovered. Theoretically speaking, this number does sound 
encouraging and one might expect the antibiotic pipeline to be pouring with new drugs. The 
reality is quite different. According to Butler and Cooper, in 2011, there were five 
compounds undergoing phase-III clinical trials, one compound was under NDA/MAA 
evaluation, 22 compounds were in phase-II, and 12 compounds in phase-I clinical trials 
(Butler & Cooper, 2011). Twenty of those compounds are derived from natural products. 
Clinical development of a drug requires certain in vitro activity, stability, and 
pharmacokinetic criteria to be met. It seems that not many of the lead secondary metabolites 
make it all the way to clinical trials and development and, eventually, drug approval. 
Nevertheless, finding an effective lead substance remains the most important starting point 
in antibiotic development. In the following text we give some examples on where some of 
these lead compounds can and have been found. 
3.1 The producing organisms 
Natural product resources, including the microbial world, are mainly unexplored both in its 
dimension and in the respect of geographic, ecological, and environmental points of view. 
There surely exist, besides the presumed numbers of microorganisms, millions of microbes 
living in remote and exotic parts of the world, or even the ones living in other organisms as 
endophytes or symbionts that await discovery and thorough study. 
3.1.1 Endophytes 
Endophytes reside in tissues between living plant cells. The relationship that they establish 
with the plant varies from symbiotic to bordering on pathogenic. Of all of the world’s 
plants, it seems that only a few grass species have had their complete complement of 
endophytes studied, although endophytic fungi have been found in each plant species 
examined. The estimated number of endophytic fungal species existing in nature is over one 
million (Petrini, 1991). As a result, the opportunity to find new and interesting endophytes 
among the myriad of plants is great.  
Plant endophytic fungi have a special ability to produce a great number of diverse bioactive 
compounds, which have been implicated in protection of its host against pathogens and 
herbivores (Wicklow et al., 2005). These structurally diverse molecules have potential 
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therapeutic value, which is why interest in screening endophytic fungi for discovery of 
novel metabolites, and more specifically novel antibiotics, has increased. The initial step in 
discovering secondary metabolites of endophytes is their successful isolation from plant 
materials. Then, the isolation and characterization of bioactive substances from culture 
filtrates is done using bioassay guided fractionation and spectroscopic methods (Strobel, 
2002). For a detailed explanation on how these endophytic microorganisms are isolated the 
reader is referred to other publications (Hallmann et al., 2006; Strobel, 2002). 
A short selection of substances with antibiotic properties that have been found in 
endophytic fungi and reported so far is included in Table 1 to provide the reader with an 
idea of how many potential lead compounds there are presently at our disposal. 
 
 
Endophytic fungal 
strain 
Host plant (family) 
Habitat of the host 
plant 
Isolated metabolite(s) 
Colletotrichum 
gloeosporioides (Penz.) 
Penz. & Sacc. 
Artemisia mongolica 
(Fisch. ex Bess.) Nakai 
(Asteraceae) 
Zijin Mountain, the 
suburb of Nanjing, 
China 
colletotric acid 
Colletotrichum sp. 
Artemisia annua L. 
(Asteraceae) 
ns 
6-isoprenylindole-3-carboxylic acid  
3b,5a-dihydroxy-6b-acetoxy-ergosta-
7,22-diene 
3b,5a-dihydroxy-6b-phenylacetyloxy- 
ergosta-7,22-diene  
3b-hydroxy-ergosta-5-ene; 
3-oxo-ergosta-4,6,8(14),22-tetraene 
3b-hydroxy-5a,8a-epidioxy-ergosta-
6,22-diene 
Phomopsis isolate 
MF6031 
Salix gracilistyla var. 
Melanostachys 
(Salicaceae) 
acquisition number 
237- 71-5282, 
Wakehurst Place, 
UK 
phomopsichalasin 
Phomopsis sp. strain 
E02018  
Erythrina crista-galli L. 
(Fabaceae) 
Boraso Stream-
Delta del Parana, 
Argentina. 
phomol 
unidentified 
endophytic fungus 
CR115 
Daphnopsis americana 
(Thymelaeaceae) 
Guanacaste 
Conservation Area 
in Costa Rica 
guanacastepenes A-O 
Periconia sp. OBW-15 
Taxus cuspidate Siebold & 
Zucc (Taxaceae) 
Kangwon region, 
Korea 
periconicin A 
periconicin B 
Guignardia sp. IFB-
E028  
Hopea hainanensis Merrill 
& Chun 
(Dipterocarpaceae) 
Hainan Island, 
China 
monomethylsulochrin 
rhizoctonic acid 
guignasulfide 
Rhizoctonia sp. strain 
Cy064 
Cynodon dactylon (L.) 
Pers. (Poaceae) 
Jiangsu Province, 
China 
rhizoctonic acid  
monomethylsulochrin  
ergosterol  
3β,5α,6β-trihydroxyergosta-7,22-diene 
Aspergillus sp. strain 
CY725 
Cynodon dactylon (L.) 
Pers. (Poaceae) 
Sheyang Port on 
the Yellow Sea 
helvolic acid 
monomethylsulochrin  
ergosterol 
3β-hydroxy-5α,8α-epidioxy- ergosta-
6,22-diene 
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Endophytic fungal 
strain 
Host plant (family) 
Habitat of the host 
plant 
Isolated metabolite(s) 
Pichia guilliermondii 
Ppf9 
Paris polyphylla var. 
yunnanensis (Franch) 
Hand.-Mazz (Trilliaceae)
Kunming, China helvolic acid 
Xylaria sp. 
YX-28 
Ginko biloba L. 
(Ginkgoaceae) 
Jiangsu and 
Shandong provinces, 
China 
7-amino-4-methylcoumarin 
Thielavia subthermophila 
INFU/Hp/KF/34B 
Hypericum perforatum L. 
(Hypericaceae) 
Harwan, Jammu and 
Kashmir, India 
hypericin 
emodin 
Twenty-nine 
unidentified endophytic 
fungal strains  
Eucommia ulmoides Oliver 
(Eucommiaceae) 
Sichuan University, 
Chengdu, Sichuan 
Province, China 
crude ethanol extract of fermentation 
broth 
chlorogenic acid 
Ampelomyces sp. 
Urospermum picroides (L.) 
F.W. Schmidt (Asteraceae)
Alexandria, Egipt 
3-O-methylalaternin 
altersolanol A 
Phoma sp.  
NG-25 
Saurauia scaberrinae 
(Actinidiaceae ) 
central highlands of 
Papua New Guinea 
phomodione 
usnic acid 
cercosporamide 
Fusarium sp. 
IFB-121 
Quercus variabilis Blume 
(Fagaceae) 
southern hillside of 
the Zijin Mountain in 
the eastern suburb of 
Nanjing, China 
cerebroside 1 
cerebroside 2 
Trichoderma ovalisporum 
PRE-5  
Panax notoginseng (Burkill ) 
F.H.Chen ex C.Y.Wu & 
K.M.Feng (Araliaceae) 
Yunnan Province, 
China 
koninginin A 
(E)-2,3-dihydroxypropyl octadec-9-
enoate 
shikimic acid 
cytosine ribonucleoside  
a compound considered to be adenine 
ribonucleoside 
Unidentified 
Ascomycete endophytic 
fungus strain 6650 
Melilotus dentatus (Waldst. 
& Kit.) Pers. (Fabaceae) 
coastal area of the 
Baltic Sea, 
Ahrenshoop, 
Germany 
4-hydroxyphthalide; 5-methoxy-7-
hydroxyphthalide 
(3R,4R)-cis-4-hydroxymellein 
Microsphaeropsis sp. 
strain 8875 
Lycium intricatum Boiss. 
(Solanaceae) 
Playa del Ingles, 
Gomera, Spain 
microsphaeropsone A 
microsphaeropsone C 
citreorosein 
enone (oxidized microsphaeropsone A) 
Microsphaeropsis sp. 
strain 7177 
Zygophyllum fortanesii 
(Zygophyllaceae) 
Gomera, Spain 
fusidienol A 
8-hydroxy-6-methyl-9-oxo-9H-xanthene-
1-carboxylic acid methyl ester 
Microdiplodia sp. strain 
7092 
Erica arborea L. (Ericaceae) Gomera, Spain 3,4-dihydroglobosuxanthone A 
Alternaria sp. strain 
JCM9.2 
Sonneratia alba J.E. Smith 
(Sonneratiaceae) 
Dong Zhai Gang 
Mangrove Garden on
Hainan Island, China
xanalteric acid I 
xanalteric acid II 
altenusin 
Chloridium sp. (J.F.H. 
Beyma) W. Gams & 
Holubova-Jchova 
Azadirachta indica A. Juss. 
(Meliaceae) 
Varanasi district, 
India 
javanicin 
Table 1. Plant endophytic fungi producing metabolites with antibacterial activity.  
ns –  not specified. 
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Another great source of antibiotic producers among endophytes is bacteria. Munumbicins 
are an example of antibacterial compounds found in these microorganisms. Gary Strobel’s 
research group has isolated and studied the Streptomyces NRRL 30562 strain, which is 
endophytic in the medicinal plant snakevine (Kennedia nigriscans), native to the Northern 
Territory of Australia (Castillo et al., 2002). Bioassay-guided HPLC purification of the 
culture broth of this endophytic bacterium led to the discovery of four major components. 
They were characterized as four functionalized peptides named munumbicins A, B, C, and 
D. The munumbicins possessed widely differing biological activities depending upon the 
target organism. For instance, munumbicin B had a mimimum inhibitory concentration 
(MIC) of 2.5 µg/ml against a methicillin-resistant strain of Staphylococcus aureus (MRSA), 
whereas munumbicin A was not active against this organism. In general, the munumbicins 
demonstrated activity against Gram-positive bacteria such as Bacillus anthracis and 
multidrug-resistant Mycobacterium tuberculosis. The most impressive biological activity of 
any of the munumbicins was that of munumbicin D against the parasite Plasmodium 
falciparum. However, in 2006, they reported that some of the munumbicins are identical to 
the better known antibiotics, the actinomycins (Castillo et al. 2006). Further effort resulted in 
the isolation of several novel antibiotics from Streptomyces NRRL 30562 with wide-spectrum 
biological activity that were termed munumbicin E-4 and E-5 (Castillo et al. 2006). Both 
compounds were tested alongside vancomycin against Escherichia coli and MRSA. The MIC 
of munumbicin E-5 against E. coli was 16 µg/ml, while the MIC for vancomycin was  
128 µg/ml. The MICs were 16 and 2 µg/ml against MRSA, respectively.  
Other antibiotic compounds of different chemical structures such as the bafilomycins  
(Yu et al., 2011), kakadumycins (Castillo et al., 2003) and many others are also produced 
by endophytic Streptomyces strains, making these bacteria worth investigating. The ability 
to make bioactive small molecules is not exclusive to microbes. Plants are rich sources of a 
great variety of compounds, but the original producer of those might be questionable. 
Opinions on this subject are divided and nobody can say for certain how many microbial 
metabolites/antibiotics considered today as marine animal or plant products, are 
produced, in fact, by symbiotic microbes in marine invertebrates and by endophytic fungi 
or bacteria living in the vascular plants. It has become generally accepted that at least for 
some compounds isolated from marine invertebrates, and in several cases from higher 
plants, the actual producers are the symbiotic microbes; bacteria, cyanobacteria, algae, or 
endophytic fungi. Indeed, several bioactive metabolites (e.g. taxol, bryostatin, 
theopalauamide, caphalomannin, etc.) have been proven to originate from symbiotic or 
endophytic microbes and not the “higher” (host) organisms (Berdy, 2005; Newman & 
Cragg, 2004). 
3.1.2 Insects 
Insects represent 80% of all fauna and are the most widespread group within the animal 
kingdom. Furthermore, some of these organisms such as cockroaches live in the filthiest 
places known to man and thrive in such conditions (Lee et al., 2011). 
An investigation of the potential antibacterial activity in various tissues of the desert 
locust (Schistocerca gregaria) and American cockroach (Periplaneta americana) was 
undertaken at the School of Veterinary Medicine and Science, University of Nottingham. 
Brain lysates of locust and cockroach exhibited powerful broad-spectrum antibiotic 
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properties (>90% bactericidal effects) against MRSA and neuropathogenic E. coli K1, strain 
E44 (a cerebrospinal fluid isolate from a meningitis patient, O18:K1:H7), a spontaneous 
rifampicin-resistant mutant (Lee et al., 2011). A preliminary test suggested that the active 
substance is proteinaceous in nature. Brain lysates had no cytotoxic effects on human 
brain microvascular endothelial cells, suggesting that the putative target(s) is not present 
in eukaryotic cells. By combining size-exclusion spin columns and fast-performance liquid 
chromatography, eight different molecules (3–10 kDa in molecular mass) in brain lysates 
were identified that were toxic both to MRSA and neuropathogenic E. coli K1. 
Higher insects protect themselves against bacterial infection by rapid synthesis of a battery 
of potent antibacterial peptides. Antimicrobial peptides (AMPs) have become recognized as 
important components of the nonspecific host defense or innate immune system in a variety 
of organisms including bacteria, fungi, plants, insects, birds, crustaceans, amphibians, and 
mammals (Zasloff, 2002). In order to overcome the problem of multi-resistant pathogenic 
bacteria, it is imperative to discover and clinically develop agents selectively toxic to 
bacteria that act on new targets which have not yet experienced selective pressure in the 
clinical setting. The research group of Laszlo Otvos has prepared derivatives of native 
proline-rich antibacterial peptides which exhibit these required features. As a lead they used 
pyrrhocoricin (Fig. 2), a peptide their group originally isolated from the European sap-
sucking bug Pyrrhocoris apterus (Cociancich et al., 1994). In a couple of publications they 
report that pyrrhocloricin is non-toxic to eukaryotic cells and healthy mice, has good activity 
against model bacterial strains in vitro and when administered intravenously in vivo, and can 
protect mice from systemic E. coli challenge (Cudic et al., 2002; Cudic et al., 2003; Otvos et 
al., 2000a). Although pyrrhocoricin is toxic to infected animals at a high dose (50 mg/kg), its 
derivative in which the peptide is protected from exopeptidase cleavage by replacement of 
the N-terminal Val1 with 1-amino-cyclohexane-carboxylic acid and the C-terminal Asn20 
with acetylated 2,3-diamino-propionic acid lacks this high dose toxicity and shows 
improved protease resistance, while maintaining the in vitro and in vivo efficacy over a 
broad concentration and dose range. Even more importantly, pyrrhocoricin and the 
derivative seem to have a completely new mechanism of action which makes the likelihood 
of fast accumulation of resistant strains insignificant. Native pyrrhocoricin kills the sensitive 
species by binding to DnaK, the 70-kDa bacterial heat shock protein (Otvos et al., 2000b). 
Remarkably, pyrrhocoricin does not bind to the human equivalent protein Hsp70, indicating 
the potential of this peptide as a drug lead to treat human or animal infections. 
A list of antimicrobial peptides in clinical trials was published in 2004 (Andres & Dimarcq, 
2004), and to date none of the peptides described has obtained FDA approval for any of the 
various clinical indications. 
3.1.3 Marine (micro)organisms 
The annual Marine natural products report has been published continuously since 1984 
(until 2002 by John Faulkner (Faulkner, 2002) and later by Blunt et al. (Blunt et al., 2011)). 
The 2011 report states that 1011 new compounds of marine origin were described in 
literature in 2009 alone, proving that the oceans are a vast resource of diverse natural 
products, primarily from invertebrates such as sponges, tunicates, bryozoans, and molluscs, 
and from marine bacteria and cyanobacteria (Donia & Hamann, 2003). 
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Fig. 2. Structures of pyrrhocoricin, pestalone, psammaplin A, and pleuromutilin. 
Research conducted with a marine fungus of the genus Pestalotia isolated from the surface of 
the brown alga Rosenvingea sp. collected in the Bahamas, lead to the discovery of pestalone 
(Fig. 2), a new chlorinated benzophenone antibiotic, which has potent antibiotic activity 
against MRSA, with a MIC of 37 ng/mL, and vancomycin-resistant Enterococcus faecium, 
with a MIC of 78 ng/mL (Cueto et al., 2001). The potency of this agent toward drug-resistant 
pathogens suggests that pestalone should be assessed in more advanced infectious diseases 
animal models. Interestingly, pestalone is produced in the mixed fermentation of a marine 
fungus, Pestalotia sp. (strain CNL-365) and an unidentified, antibiotic-resistant marine 
bacterium (CNJ-328), highlighting the complex dependence of metabolite biosynthesis on 
culture conditions and the potential for enhanced antibiotic production through cross-
species induction. This observation clearly demonstrates that pestalone is a product of 
fungal biosynthesis in response to an external trigger, suggesting that this method may have 
use for drug discovery in the future (Cueto et al., 2001). 
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Sponges alone produce more than 3300 antibiotics and other bioactive compounds. It is 
noteworthy to mention that these isolated “animal” compounds very frequently show 
surprising analogy to microbial or algal products. As with the secondary metabolites 
produced by plants and their endophytes, it is not surprising that in numerous occasions the 
active compounds isolated from sponges proved to be derived from the microorganisms 
living in symbiosis with their host (Berdy, 2005). Marine microbes are particularly attractive 
because of the high potency required for bioactive compounds to be effective in the marine 
environment, due to the diluting effect of seawater (Zhang et al., 2005).  
Psammaplin A (Fig. 2) is a symmetrical bromotyrosine-derived disulfide natural product 
isolated from the Psammaplysilla sponge (Arabshahi & Schmitz, 1987), with in vitro 
antibacterial activity against MRSA. Based on the structure of psammaplins, Nicolaou et al. 
produced a library of 3,828 compounds. Six of these optimized antibacterial agents 
possessed more than 50-fold higher activities than the natural product, demonstrating MIC 
levels in methicillin-resistant/intermediate vancomycin-resistant strains of S. aureus at less 
than 1µg/ml. In order to construct these heterodimeric disulfide analogues they used a 
novel combinatorial disulfide exchange strategy, thus demonstrating the power of modern 
combinatorial techniques when applied to a base active structure from nature (Newman & 
Cragg, 2004; Nicolaou et al., 2001a; Nicolaou et al., 2001b). Most significantly, a number of 
these agents exhibited increased selectivity against bacterial cells over fibroblasts and 
lymphocytes as compared to the natural product. 
In similar efforts of the marine natural products community, many antibacterial agents have 
been identified from sponges (Laport et al., 2009). Despite their high number, none of them 
has yet been involved in clinical trial as an antibacterial agent. 
3.1.4 Higher fungi 
Among the eukaryotes, fungal genomes are rich in biosynthetic gene clusters for encoding 
small molecule production (Miao & Davies, 2010). Fungi are the second largest group of 
eukaryotes next to insects and exceed not only the bacteria and actinomycetes, but also the 
higher plants in terms of the number of potential existing species. It looks like the world of 
fungi is one of the largest reservoirs for isolating further bioactive metabolites (Berdy, 2005).  
Besides the discovery of new compounds, the re-evaluation of “old” substances, including 
microbial metabolites formerly believed to be inactive, have proven to be just as important. 
On numerous occasions such compounds have been shown to be active in later 
investigations, or were rediscovered by screening a different stock of microbes, or with 
specific screening methods. It is unpredictable how many “new” bioactive metabolites will 
be discovered in this way (Berdy, 2005). 
An excellent example of this is pleuromutilin (Fig. 2). It was initially discovered in 1951 in a 
study of the culture broth of the edible basidiomycete mushroom Pleurotus multilus 
(Kavanagh et al., 1951). After more than 50 years, a derivative of pleuromutilin, named 
retapamulin, was approved in 2007 by the FDA for the treatment of bacterial skin infections. 
The low oral bioavailability of retapamulin seems to have been improved in the new 
derivative named BC-3205, which is being investigated in phase-I clinical trials by Nabriva 
(Butler & Cooper, 2011). Another pleuromutilin derivative, BC-7013 ([14-O-[(3-
hydroxymethyl-phenylsulfanyl)-acetyl]-mutilin]), is in phase-I clinical trials as a topical 
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antibiotic, while BC-3781 successfully completed a phase-II clinical trial for the treatment of 
acute bacterial skin and skin structure infections (ABSSSI) (US National Institutes of Health, 
2011). Nabriva’s lead product BC-3781 is the first of a new class of systemically available 
pleuromutilin antibiotics for the treatment of serious skin infections and pneumonia. BC-
3781 is being developed for both oral and intravenous formulations. 
4. How do we search for natural antibiotics? 
Although the number of antibiotics present in nature may truly be huge, many of them are 
already known or will not be usable (i.e., will not display selective toxicity to bacteria, will 
be too weak, or will lack the desired pharmacokinetic properties) (Pelaez, 2006). Yet 
historically, the development of antibiotics from natural templates has seen an 
unprecedented gain compared to the de novo synthesis. The conventional discovery process 
of antibiotics from the pool of microbial natural products requires having a given 
microorganism grown in conditions appropriate to induce the production of (the desired) 
metabolite, which is then extracted and tested in a screen able to detect it as a hit. Finally, 
the compound has to be isolated from the original mixture and identified. 
Identification of novel antibiotic types that occur in relatively low frequency in nature 
clearly requires innovative detection and characterization techniques. Numerous 
promising microbiological approaches supplemented with bioinformatic, genetic, and 
structural methods have been developed over the last decade to address the issue (Fig. 3).  
 
Fig. 3. Postgenomic approaches in antibiotic discovery (adapted from (Davies, 2011)). 
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These allow for laboratory culturing of previously inaccessible microorganisms as potential 
antibiotic producers, extracting genomes of uncultivable species from environmental 
samples or mining for and inducing expression of cryptic biosynthetic clusters to yield yet 
untapped secondary metabolites, direct solvent extraction and subsequent characterization 
of low molecular weight compounds from natural samples, and high-throughput 
fermentation of underexplored bacterial strains. In addition, intelligent strategies to avoid 
antibiotic rediscovery have been devised. In the following sections, we critically review the 
recent methodology of antibiotic discovery. 
4.1 Improvements in screening platforms 
Parallel fermentation coupled with whole-cell assays for antibiotic activity remains the 
cornerstone of antibiotic discovery. Yet, introduction of certain implementations are vital 
to detect antibiotic compounds that occur at low concentrations or to prevent rediscovery 
of old antibiotic types. For example, researchers at Merck developed a highly sensitive 
assay for detection of inhibitors of β-ketoacyl-[acyl-carrier-protein] synthase II (FabF), a 
component of FASII pathway, by introducing a plasmid that encodes antisense RNA 
against the fabF transcript in S. aureus (S.B. Singh et al., 2007). Thereby, FabF expression is 
knocked down to growth-limiting levels, resulting in a strain that is hypersensitive to 
FASII pathway inhibitors. The mutant is assayed in parallel with the control wild-type 
strain to monitor for differential sensitivity. This combination of target-based and whole-
cell screening had a high hit rate of 0.3% and led to discovery of platensimycin, a broad 
spectrum Gram-positive antibiotic, from a screen of ~250.000 natural product extracts 
(Wang et al., 2006). Another interesting approach was reported by a team at Cubist 
Pharmaceuticals. They constructed a model target organism (CM400) by using E. coli 
engineered to harbor multiple resistance markers (conferring resistance to 16 most 
frequent antibiotics) (Baltz, 2006; Gullo et al., 2006). In this way, the hits are preselected to 
belong to new antibiotic classes. Additionally, a derivative of CM400 (termed CM435) 
with increased permeability was created to achieve enhanced sensitivity to antibacterial 
compounds. However, this strategy requires enormous input of natural products to be 
tested due to extremely low hit rates. 
4.2 High-throughput fermentation focusing on relevant microorganisms 
It is absolutely essential to screen extracts of only those organisms that have the capacity to 
produce complex secondary metabolites. The size of the genome provides a good indication 
of metabolism complexity; actinomycetes, the most important group of antibiotic producers, 
have large genomes relative to other bacteria with up to 10% of all genes devoted to 
production of secondary metabolites, such as nonribosomal peptides and polyketides (Baltz, 
2008; Donadio et al., 2007). Using relatively selective antibiotics, bacterial populations can 
empirically be enriched for rare species (Baltz, 2006 and references cited therein) after which 
microbial diversity in the remaining population is conveniently assessed by 16S rRNA gene 
sequencing (Amann et al., 1995; Rajendhran & Gunasekaran, 2011). If the population is 
considered interesting in terms of secondary metabolite-producing potential, thousands of 
strains are typically screened for antibiotic activity. This, however, is no trivial task and 
represents a bottleneck of screening for antibiotics. 
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An obvious solution to increasing the throughput of fermentation is to miniaturize initial 
batches (i.e., perform microfermentations), allowing accommodation of larger numbers of 
strains and/or growth conditions simultaneously. At Cubist Pharmaceuticals they faced the 
challenge by encapsulating individual environmental microbes in ~2 mm alginate 
macrodroplets and growing them in media favouring actinomycete growth supplemented 
with antibiotics against single-cell eubacteria and fungi. This technology supports the 
fermentation and screening of up to 10 million actinomycetes per year (Baltz, 2006; Gullo et 
al., 2006). Similarly, a method that couples bacterial encapsulation in gel microdroplets with 
flow cytometry to detect those beads that contain microcolonies was reported (Zengler et al., 
2002). This enables rapid isolation of bacterial strains from environmental samples in order 
to prepare pure cultures for subsequent studies. 
4.3 New cultivation techniques 
Since the vast majority of prokaryotes are not amenable to simple cultivation (indeed, only 
~0.1% of existing prokaryotes have been cultured so far (Alain & Querellou, 2009)), 
numerous efforts to develop strategies for efficient bacterial growth in vitro have been made. 
Undoubtedly, expanding the accessible pool of antibiotic producers will raise the odds of 
discovering novel antimicrobials. 
Attempts to recover diverse microorganisms from environmental samples by manipulating 
growth conditions (e.g. media formulation, light, temperature, agitation) have shown some 
success (Köpke et al., 2005; Uphoff et al., 2001; Zengler et al., 2002). However, the approach 
is strictly empirical and the yield is rather unpredictable. Moreover, the projects are often 
endangered by overgrowth of (common) opportunistic fast-growing microorganisms, 
especially when using nutrient-rich artificial media (Alain & Querellou, 2009). Furthermore, 
in vitro culturing attempts typically disregard the importance of chemical components or 
physical conditions of natural growth environments. Culturing in situ or under simulated 
natural conditions was demonstrated to be successful in some instances. For example, new 
bacteria were isolated from intertidal marine sediments using diffusion chambers and 
growth in seawater aquarium (Kaeberlein et al., 2002). The membranes of diffusion 
chambers allow for exchange of chemicals between the chamber and the environment, while 
restricting cell movement. Interestingly, two isolates easily grown in diffusion chambers 
could only be maintained in petri dishes in coculture, indicating the requirement for specific 
signaling between the two species as a marking of a favorable environment. Other studies 
found specific physical requirements for culturing different strains, such as high hydrostatic 
pressure (Alain et al., 2002) or carriers for adhesion (Yasumoto-Hirose et al., 2006). 
Previously uncultured bacteria were successfully recovered from soil, marine sediments or 
activated sludge by these innovative methods. Unfortunately, they are rather specialized 
and as a result were not adopted by a wider scientific community. 
4.4 Direct isolation of metabolites from environmental samples 
Direct sampling of natural products from the environment represents an alternative to 
microbial strain isolation and fermentation for production of secondary metabolites. In 
theory, this grants access to the complete metabolome, which cannot be retrieved by 
classical means because most microbes defy cultivation (see section 4.3). On the other 
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hand, environmental concentrations of numerous antibiotics are too low to be readily 
detected by conventional analytical methods or activity screening. Modern liquid 
chromatography-mass spectrometry (LC-MS) instruments combine high resolution and 
high sensitivity with the power of structure determination, and as such hold great 
potential for analysis of secondary metabolites in organic extracts of various, complex 
environmental samples (Davies, 2011). 
An exciting new field in natural product research is imaging mass spectroscopy (IMS) 
(Esquenazi et al., 2009). Application of IMS enables analysis of spatial distribution of 
compounds in a substrate, such as a plant organ or a marine sponge. This method led to 
identification of various (endo)symbiotic microorganisms as true producers of secondary 
metabolites which were initially erroneously attributed to the host organism (Esquenazi et 
al., 2009; Simmons et al., 2008). Another promising application of IMS is the so-called thin 
layer agar natural product MALDI-TOF imaging. Here, microorganisms are grown on a thin 
agar film deposited on a MALDI plate, after which the sample is covered with a matrix and 
analyzed by MALDI. Thus, a complete set of metabolites produced under different culturing 
conditions (even in cocultures to trigger interspecies interactions) can be examined (Yang et 
al., 2009). 
Finally, the soaking of potential ligands from environmental extracts into crystals of 
recombinant proteins was proposed as another method to enrich for and analyze the 
structures of compounds with desired affinity to bacterial targets (Davies, 2011). Ideally, 
structural information gathered on the isolated secondary metabolite should assist in 
identification of the biosynthetic pathway from (meta)genomic library sequences (see 
sections 4.5 and 4.6). 
4.5 Genome mining for cryptic metabolic pathways 
In prokaryotes and fungi, gene encoding enzymes involved in secondary metabolite 
production are often clustered together. Polyketides and nonribosomal peptides (some of 
which are well established antibiotics) are typically assembled by massive synthetases of 
modular nature, wherein the modules consist of multiple domains, each being accountable 
for recognizing and fastening a specific substrate or catalyzing a sequential reaction step 
(e.g. building block activation, condensation, or tailoring) (Walsh & Fischbach, 2010). 
Therefore, the products of such assembly lines are said to be templated. Genome sequencing 
has revealed that certain microbes, especially many actinomycetes, harbor many (20 or 
more) biosynthetic gene clusters, most of which are cryptic (i.e., direct the production of 
unknown natural products) (Davies, 2011). This indicates that there are numerous complex 
secondary metabolites remaining to be discovered. The fact that polyketides and 
nonribosomal peptides are templated can aid in bioinformatic identification of genomic loci 
encoding biosynthetic pathways as well as provide clues to the structure and properties of 
metabolic products that are essential in developing methods for their detection and isolation 
(Fig. 4). If the product possesses the desired antibiotic activity and has favorable 
physicochemical properties, it is chosen as drug lead and platforms for sufficient production 
must be set up in order to support preclinical development. Strategies to elicit cryptic 
biosynthetic gene expression have been devised but will not be covered here. Readers 
interested in this topic are referred to two excellent recent reviews (Baltz, 2011; Chiang et al., 
2011). 
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Fig. 4. Strategies for identifying metabolic products of cryptic gene clusters (compiled and 
adapted from (Challis, 2008)). Based on homology searches, novel biosynthetic gene clusters 
are predicted from genome sequences. A) The modular structure of synthetases allows 
assumptions on putative substrates, which together define structural and physicochemical 
features of secondary metabolites that guide the design of isolation procedures.  
B) Alternatively, the organism can be grown on a medium containing putative precursors 
labeled with stable isotopes to facilitate subsequent identification of final products by 2D 
NMR. C) The predicted synthetase can be expressed using recombinant DNA techniques 
and used in isolated form to reconstitute the product in vitro. D) The putative biosynthetic 
gene cluster can be knocked out and metabolites in culture supernatants analyzed by LC-MS 
in comparison to the metabolome of the wild-type strain. E) Similarly, the entire 
biosynthetic gene cluster-containing locus can be transferred to a heterologous host. The 
metabolome of the transgenic strain is compared to the untransformed host. F) Attempts to 
force expression of cryptic biosynthetic genes using induction of various endogenous 
activators have also been made. 
4.6 Metagenomics 
The term metagenomics refers to “the application of modern genomic techniques to the 
study of microbial organisms directly in their natural environments, by-passing the need for 
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isolation and laboratory cultivation of individual species” (Miao & Davies, 2009). At the 
heart of metagenomics lies the recovery and sequencing of genomes of entire microbial 
communities occupying diverse ecological niches. Thereby, even the uncultivable 
microorganisms are addressed. The gathered genetic information is then scanned for 
potential biosynthetic genes in the hope for identification of novel natural products in a 
similar way as previously discussed (see section 4.5) (Banik & Brady, 2010; Miao & Davies, 
2009). Alternatively, metagenomic expression libraries can also be directly assayed for 
functional products (Brady, 2007). However, due to methodological obstacles no complex 
biosynthetic gene clusters have been recovered from environmental DNA (eDNA) to date 
(Miao & Davies, 2009). 
One of the biggest problems in metagenomics is the inefficient cloning of extremely large 
DNA segments needed to harbor intact gene clusters for preparation of metagenomic 
libraries. The transformation of vectors such as cosmids or bacterial artificial chromosomes 
to surrogate hosts is the main factor that limits construction of libraries with acceptable 
complexity. Moreover, the host might not efficiently express biosynthetic transgenes 
because of differences in codon usage or incompatibility of promoters (Miao & Davies, 2009; 
B.K. Singh & Macdonald, 2010). Finally, it is imperative to enrich microbial populations for 
strains with potential to produce complex secondary metabolites (see section 4.2) (Miao & 
Davies, 2009) or enrich isolated eDNA samples for genes of interest (Banik & Brady, 2010) 
before the metagenomic library is constructed to minimize background. 
5. Modification of natural scaffolds 
Natural resources are and will continue to provide structurally and mechanistically new 
molecules that serve as useful drugs or lead compounds. One should realize, however, that 
natural antibiotics rarely possess the appropriate characteristics to be directly considered as 
drugs. Instead, they typically need to undergo chemical modifications in order to be 
translated into functional drugs. The goal of such projects may be to improve the 
pharmacokinetic properties of drug leads (e.g. increase stability and bioavailability) or 
produce derivatives with higher activity and wider antibiotic spectrum (e.g. by 
incorporating moieties to evade bacterial efflux pumps or to engage into additional 
interactions with the bacterial target protein). Both focused rational design and 
combinatorial chemistry approaches backed up by structural studies of targets complexed 
with natural or synthetic antibacterials and their derivatives have resulted in numerous 
optimized antibiotic drugs (Brötz-Oesterhelt & Sass, 2010; Butler & Cooper, 2011; Newman 
& Cragg, 2007). 
Combinatorial biosynthesis is a rapidly expanding field in natural antibiotic optimization 
(Baltz, 2008; Kopp & Marahiel, 2007). The modular nature of polyketide synthases and 
nonribosomal peptide synthetases enables generation of natural product variants by 
exchange or alteration of individual modules within the bioassembly line. Many polyketides 
and nonribosomal peptides are not amenable to chemical synthesis and semisynthetic 
modification due to extreme structural complexity. Here, chemoenzymatic approaches 
represent a viable alternative. One prominent example is the generation of a library of 
lipopeptides based on the daptomycin structure (Nguyen et al., 2006). The daptomycin 
biosynthetic pathway was engineered by module and subunit exchange, and inactivation of 
a tailoring enzyme. Some of the lipopeptide variants produced in fermentations were highly 
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active antibiotics. Another group used error-prone PCR to generate gene mutants of 
glycosyltransferase that catalyses glucosylation of macrolide antibiotic oleandromycin 
(Williams et al., 2007). Thereby, they managed to broaden the specificities of the 
glycosyltransferase for acceptor substrates as well as donor nucleoside diphospho-sugars. 
Such innovative chemoenzymatic strategies combined with semisynthetic modification of 
natural products (novel and old) seem to provide a powerful tool for the development of 
new and improved antibiotics. 
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